Latigo Biotherapeutics adopts amended and restated bylaws tied to IPO close
Reuters2026/08/10 20:04- Latigo Biotherapeutics adopted amended and restated bylaws effective Aug. 10, 2026 in connection with its IPO closing.
- It also filed an amended and restated certificate of incorporation in Delaware, effective immediately before the IPO close.
- The IPO sold 19,200,000 common shares at USD 18 per share, raising about USD 345.6 million in gross proceeds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Argus raises Dell's target price to $560
Yelooo Integra Datanet corrects July securities holders registration report
Cakra Buana Resources Energi shareholder Republik Capital cuts stake to 9.3% from 11.3%
Preferred shares of South Korean companies are trading at a record 45% discount in ten years; Samsung's 110 trillion won buyback plan may help eliminate the "Korea discount"
Samsung Electronics' highly anticipated stock buyback plan is raising investor expectations that the South Korean giant will purchase non-voting preferred shares, narrowing their deep discount and setting a precedent for other companies.
Crypto prices
More
